NEW YORK (GenomeWeb) – The US Department of Justice said on Thursday that Biotheranostics has agreed to pay $2 million to settle allegations that the company improperly billed Medicare for molecular breast cancer tests. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.